Inovio Pharmaceuticals Inc. (INO) on Wednesday announced positive efficacy results for an open-label Phase 2 trial of VGX-3100 to treat HPV-16 and HPV-18-associated vulvar dysplasia.
The company said that a reduction of 25 percent or more in HPV-16/18-associated vulvar HSIL (high-grade squamous intraepithelial lesion) was observed for 63 percent, or 12 of 19 trial participants treated with VGX-3100 at six months post-treatment.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.